Next week, Tuesday Top Ten will be taking a short break due to some other pressing matters. That means you’ll have to enjoy this week’s links TWICE as MUCH, so I conveniently doubled up on a couple! Don’t forget to leave your comments on these articles at the bottom of the post. Have suggestions for Tuesday Top Ten? Let me know.
10. This was sad to read, but not entirely surprising. The number of NIH-funded scientists dropped this year, says Science Insider.
9. Science Shot covered an interesting study that found not all people experience pleasure from listening to music. The research group even made a quiz that you can take to see if you’re a music appreciator (I am, but that was the result I expected).
8. A man with ambitions to be a professional drummer lost his arm, so a researcher kindly made him a new one. This is no ordinary prosthetic – it’s got super drumming powers! Via New Scientist.
7. Nature Jobs Blog had some great tips on how to make your resume and CV stand out.
6. The Science Writers’ Handbook wrote a summary on an incredibly fascinating story – the ghost writer behind the unauthorized autobiography of WikiLeaks mastermind Julian Assange. The full article reads more like a novel, but a gripping one at that. A candid account of how the autobiography became “unauthorized.”
5. “A blood test for Alzheimer’s disease?” The Science NOW headline says it all.
4. I’ve been saying this for years, and now Nature Jobs Blog is agreeing with me: Scientist should be more active on social media.
3. A follow up to the link last week about high-protein diets: The Wall Street Journal digs deeper into the problems associated with high-protein diets.
2. Can you train your brain to like healthy food? Scientists have shown they can train you to prefer certain junk foods over others, so healthy foods are just one more step away! Via Science NOW.
1. With impending drug trials for Down syndrome and Fragile X, doctors are looking into how the intellectually disabled can understand the risks and benefits of enrolling in clinical trials. Via The Wall Street Journal.